Home / People / Theo Godfrey
Portrait ofTheo Godfrey

Theo Godfrey

Partner

Contact
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
London
EC4N 6AF
United Kingdom
Languages English

Theo is a Partner in CMS´s Corporate Group. He advises on a wide range of corporate transactions, including acquisitions, disposals, private equity and venture capital transactions and joint venture arrangements, for both private and listed clients. Theo has a particular focus on the Life Sciences & Healthcare and Technology, Media & Communications sectors.

Clients include established domestic and international companies, growing businesses, institutional investors, high net-worth individuals and management teams.

Theo co-manages CMS´s equlP Life Sciences programme, which supports early/growth stage life sciences business.

He also volunteers as a mentor and advisor to life sciences start-ups through BioCity´s Expert Network.

more less

"Theo Godfrey is really helpful. He explains things very well, is always available to speak with us and somehow to accommodate urgent requests. He is very friendly and helpful and very keen to ensure the best outcome for the client."

Legal 500, 2021

Relevant experience

Life Sciences & Healthcare

  • Syncona, the LSE listed life sciences investment fund, on its $475m disposal of diagnostic imaging business Blue Earth Diagnostics to Bracco lmaging.
  • Essential Pharmaceuticals, a pharma business, on the sale to Rosemont Pharmaceuticals of its oral liquids portfolio and the acquisition from Rosemont Pharmaceuticals of a portfolio of products, in each case through a new corporate vehicle.
  • Contura on the sale to Axonics of Bulkamid, a treatment for stress urinary incontinence, for $200m in upfront consideration plus deferred consideration of up to $35m, payable in a combination of cash and Axonics stock.
  • Catalent, lnc., a NYSE listed provider of drug delivery technology and development solutions, on  the UK aspects of its $140m acquisition of Juniper Pharmaceuticals, lnc., a NASDAQ listed provider of women´s health therapeutics.
  • The Crick lnstitute, a biomedical discovery institute, on the arrangements between its JV parties, including the Medical Research Council (MRC), Cancer Research UK, the Wellcome Trust and a number of universities.
  • VC funds Syncona, Albion Capital, ALSA and Epidarex on a number of investments.

TMT - Technology, Media & Telecommunications

  • Clearscore, the credit marketplace business, on its $200m investment from lnvus Opportunities.
  • Modulr, the digital payments provider, on its $19m funding round led by Highland Europe and subsequently on a 29 investment by PayPal.
  • Arm and Thales, the shareholders of Trustonic, a developer of cyber security solutions for smart phones and loT devices, on its sale to EMK Capital.
  • MXLG, a joint venture between MXC, the AlM-listed technology focused adviser and investor, and Liberty Global, the NASDAQ-listed international TV and broadband company, on its acquisition of Koris Communications, a managed telecommunications service provider.
  • JPMorgan Chase on its strategic investments in fintech companies Mosaic Smart Data, Access Fintech and H4.
  • VC fund TempoCap on a number of investments and disposals in tech and fintech businesses.
  • Moonbug Entertainment Limited on its acquisition of El Bebe Productions Limited, the producer of pre-school animation content including the "Little Baby Bum", "LBB Junior" and "KiiYii" series.
  • Dentsu Aegis Network, the global media group, on its acquisitions of:
    • Tempero, a social media moderation business.
    • John Brown Media, a content marketing agency.
    • Gleam Futures, a digital talent agency.
    • B2B International, an international market research business.
more less

Education

  • 2004 – BSc (Economics and Economic History), London School of Economics and Political Science, London
  • 2005 – Graduate Diploma in Law, Nottingham Law School, Nottingham
  • 2006 – Legal Practice Course, Nottingham Law School, Nottingham
more less
21/02/2017
Olswang advises Content Media Corporation on its sale to Kew Media Group
This article was produced by Olswang LLP, which joined with CMS on 1 May 2017. International technology, media and telecoms law firm Olswang has advised London and LA-based film, television and digital...
02/09/2016
Olswang advises German media group Hubert Burda Media on its investment...
This article was produced by Olswang LLP, which joined with CMS on 1 May 2017. International technology, media and telecoms law firm Olswang has advised German media group Burda on its acquisition of...
20/01/2016
Olswang advises Munich headquartered agency on the acquisition of Seven...
This article was produced by Olswang LLP, which joined with CMS on 1 May 2017. The M&A team at international technology, media and telecoms law firm Olswang has advised Munich-based C3 (Creative Code...

Feed

16/11/2023
On the Pulse Webinar Series 2023 - Autumn
On the Pulse webinar series brings you updates on the latest legal and commercial developments in the life sciences & healthcare sector. The Autumn edition will see our CMS sector specialists cover: Commercial - Deal landscape and transaction trends in the Life Sciences SectorDispute Resolution - The midnight clause: why choice of law and jurisdiction clauses matterPublic Procurement - Typical pitfalls to be avoided in a procurement process for pharma and medical devices suppliesequIP - Pitfalls for life sciences start-ups to avoidEach webinar will be one hour in length with a 15-minute Q&A session. To register for the full series or just the topics of interest to you, click on the registration links below. To watch the Spring webinars in the On the Pulse series, visit here.
22/03/2023
ESG investing - a recap for the Life Sciences and Healthcare sector
Environmental, Social, and Governance (“ESG”) investing is the consideration of ESG factors alongside financial factors in the investment decision-making process, which can range from the integration of ESG for risk purposes through to investing for particular sustainability outcomes. By integrating ESG considerations into financial decisions, investors can align investments with their values, while pursuing sustainable economic growth and mitigating risk.
10/02/2021
Life Sciences - The road to recovery
Covid-19 has put the life sciences industry in the spotlight. The sector has pulled together to care for those impacted by the virus and in the race to find a vaccine. There have been col­lab­or­a­tions...
03/09/2020
The future of buyer-friendly terms in M&A
Whilst clients report some ‘green shoots of recovery’ across various sectors, it remains to be seen whether these will flourish or whether they will wither with the onset of autumn and a possible...
05/08/2020
CMS advises Autolomous on fundraising
International law firm CMS has advised Autolomous, a developer of innovative software for cell and gene therapy manufacturers, on its seed funding round led by a US-European investor con­sor­ti­um. The...
01/07/2019
CMS advises sellers in relation to $450m sale of Blue Earth Diagnostics
International law firm CMS has advised the sellers in relation to the sale of Blue Earth Diagnostics to diagnostic imaging business Bracco Imaging. Bracco Imaging will acquire all outstanding shares of...
13/10/2017
CMS advises Autolus Ltd on $80m series C financing
CMS has advised Autolus Ltd, a clinical-stage bio­phar­ma­ceut­ic­al company focused on the development and com­mer­cial­isa­tion of next-generation engineered T-cell therapies, on its $80m series C financing...